mbg-logo-500px

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. 

mbg-portfolio-sidebar-hepaterambg-portfolio-sidebar-neuromaxmbg-portfolio-sidebar-infectexmbg-portfolio-sidebar-eleventambg-portfolio-sidebar-osterosmbg-portfolio-sidebar-photonicsmbg-portfolio-sidebar-oncomaxmbg-portfolio-sidebar-metamaxmbg-portfolio-sidebar-cardionova

Maxwell Biotech Group

Maxwell Biotech Group (MBG) is a development partner and financial resource for biotechnology companies. MBG provides investment capital and access to an established infrastructure for conducting high-quality clinical trials in Russia, and helps enable the rapid and cost-effective achievement of clinical objectives. Our unique business model can add value to our partners’ pipelines and provide a commercialization path to one of the most lucrative emerging markets. MBG relies on an experienced international team of managers and financial and industry experts, with representatives in Boston (USA).

Maxwell Biotech Group currently has 9 biotech companies in its portfolio, which are engaged in the development of 11 innovative clinical stage drugs. Four products are in the registration phase of clinical studies.

© Maxwell Biotech Group Ltd.

TOP